Healthy subjects, and patients diagnosed with occlusion or stenosis of the major cerebral arteries, neuroinflammatory disorders, neurodegenerative disorders, vascular dementia, and epilepsy
Conditions
Interventions
Subjects shall have an intravenous access route established in an upper limb vein using either a hypodermic needle or an indwelling needle, and receive a single intravenous dose of [18F]SynVesT-1 at 3
Sponsors
The University of Osaka
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Individuals from whom written consent for study participation has been obtained Healthy subjects aged 20 to 60 years without brain or neurological disorders
Exclusion criteria
Exclusion criteria: Pregnant or breastfeeding individuals Individuals with gross organic brain abnormalities Other individuals deemed unsuitable by the principal investigator or co-investigators
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Quantitative indicators such as SUVR obtained from synaptic function PET | — |
Secondary
| Measure | Time frame |
|---|---|
| Structural changes in the brain, volumes of grey matter, white matter, etc., axonal and myelin function, as determined by MRI. Cerebral circulatory metabolism, as determined by O-15 PET. | — |
Countries
Japan
Contacts
Public ContactDaisuke Katayama
The University of Osaka Department of Nuclear Medicine
Outcome results
None listed